Business

<< Previous   of   Next >> (click to enlarge) Employee Bjorn Bjorkman stirs slurrying resin that will be used to filter and purify a batch of proteins. Suzanne Schmid / The Herald  (click to enlarge) Victor Orlov (left) and Michael Larson use a giant filter to purify a batch of proteins at CMC, a Danish company that is purchasing former drug manufacturing facility ICOS in Bothell.   ADVERTISEMENT   CONTACT THE HERALD Mike Benbow, Business Editor benbow@heraldnet.com   Published: Wednesday, December 5, 2007 Jobs likely to grow at Bothell biotech once slated for closure The workforce at the former ICOS Corp. will likely expand after CMC Biopharmaceuticals completes its acquisition of the company. By Eric Fetters Herald Writer BOTHELL -- Denmark-based CMC Biopharmaceuticals plans to retain all the employees and even expand the workforce at a biotechnology manufacturing plant once operated by ICOS Corp. and which had been expected to close its doors soon. Mads Laustsen, CMC's chief executive officer, discussed Tuesday his intentions for the Bothell plant after announcing an agreement to buy the facility. "We want to develop into one of the largest contract manufacturing organizations on the West Coast," Laustsen said. To do that, CMC will need to add to the 127 employees in Bothell and invest to allow the facility to produce late-stage and even commercial-stage biotech drugs for others. Laustsen said new jobs could be added starting next year. The Bothell contract manufacturing facility is the last operating unit of ICOS Corp., the local biotechnology company bought for $2.3 billion by Eli Lilly & Co earlier this year. Under CMC's ownership, it is being renamed CMC ICOS Biologics. Financial terms of CMC's deal with Lilly were not disclosed. This is the first manufacturing facility in the U.S. for privately owned CMC, which got its start in 2001, Laustsen said. The company previously had business offices in Seattle and New England. ICOS' contract manufacturing business has specialized in making therapeutic proteins for clients with early-stage clinical trials. When Lilly bought ICOS in January, primarily to gain full ownership of the erectile dysfunction drug Cialis, it said from the beginning it did not intend to hold onto the plant. But local economic development officials and politicians lobbied Lilly to find a buyer for the business rather than shut it down like ICOS' local labs and business offices. While the facility stayed open to fulfill its ongoing contracts, Lilly talked to potential buyers. CMC apparently began talking to Lilly this fall, said Deborah Knutson, president of the Snohomish County Economic Development Council. "We've been waiting for this news," Knutson said. "It's a great way to end the ICOS story." Rep. Jay Inslee, who wrote letters to the chairman of Indianapolis, Ind.-based Lilly about the plant, called Tuesday's announcement a "very positive development in a tough situation." Tom St. John, the former vice president of therapeutic development at ICOS, called the plant an "excellent acquisition for CMC." "The asset they've got is that team of people there," said St. John, who's now executive vice president for Seattle startup Fate Therapeutics. He said the facility, which started early in ICOS' 17-year history, gained many repeat commercial customers. Laustsen said CMC looked at other contract manufacturing facilities across the U.S., and even found some with newer or bigger equipment. But the track record of the team at the Bothell plant stood out. Laustsen said employees at the plant received official notice Friday of CMC's intention to buy the business. Jack Faris, president of the Washington Biotechnology & Biomedical Association, said the reaction has been uniformly positive. "I've seen nothing but smiles around this place," he said while visiting the facility Tuesday. Faris characterized CMC's acquisition as a vote of confidence in the Puget Sound region's biotech industry. Assuming CMC eventually boosts production, the deal also could give Snohomish County a solid base of biotech manufacturing jobs. Already, Bayer HealthCare Pharmaceuticals -- formerly known as Berlex -- is working to gain certification for a $70-million-plus drug manufacturing plant it's built in Lynnwood. Once that is running, it will produce Leukine, an artificial form of a naturally occurring growth protein. Reporter Eric Fetters: 425-339-3453or fetters@heraldnet.com

1. Snohomish County man dies of swine flu 2. Lynnwood bank reprimanded by government 3. Police ID make of vehicle in fatal hit-and-run 4. Armed man shot by deputies in Arlington 5. IRS joins puppy mill investigation 6. Jetty Island ready for sand castles 7. Boeing's 6-month tally: 1 net order 8. Warriors & Patriots: Many American Indians served before getting full citizenship rights 9. Movin' out 10. Marshals seize swindler's home 2 - Top 10 Stories Most Talked about 3 - Top 10 Stories Most Emailed

• Warriors looking for balance • Three Scots vying for QB slot • Jackson looks for another title • Decorated veteran continues to serve as active volunteer • City Council reviewing sign regulations • Wildcats get a peek at newcomers • Lynnwood still in rebuilding mode • Shoreline feels a kindergarten growth spurt • Leave the patriotic pyrotechnics to professionals, cities urge • Trading dollars for kilowatts New PUD energy conservation programs save ... • By John Wolcott SCBJ Editor • Record crowd at Paine Field’s General Aviation Day as FHC Celebrate ... • Celebration of aviation's history and future presented in multiple venue ... • The time is ripe for small businesses to take no prisoners • EPA proposal to regulate global-warming gases would be costly for small ... • Innovation helps the town of Forks to offset tough economy • Powering the people